Belgium· BE-AMP-SAM468764-00
Pramipexol Teva 0.26 mg
A pramipexole product containing pramipexole dihydrochloride monohydrate, registered in Belgium by Teva. The same ATC class is registered in 18 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Pramipexole is registered in 18 of 19 countries.
Countries holding a registration under ATC N04BC05 (pramipexole), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 10 of them publish a price we can compare per daily dose
Pramipexole · ATC N04BC05
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pramipexole costs, country by country.
Normalised to the WHO defined daily dose (2.5 mg), the median price runs from $0.28 in United States to $5.68 in Switzerland — a ×20 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Pramipexole · price per daily dose (2.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$5.68
- IT Italy$2.62
- FR France$1.32
- US United States$0.28 (acquisition cost)
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Pramipexole Dihydrochloride Monohydrate
- Manufacturer
- Teva
- Country
- Belgium (BE)
- ATC code
- N04BC05
- ATC class
- Pramipexole
- Defined daily dose
- 2.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb3303864EUR 15.8
- be_apb7713613
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
197 interactions on record for pramipexole.
Graded by severity as the source publishes them — 51 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pramipexole · interactions on record
197 records
- 51 moderate
- 3 minor
- 138 info
Most severe, free to view
- CimetidineA02BA01moderate
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
5 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pramipexole in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCALMOLANG.L. Pharma GmbH, Lannach
- United KingdomMirapexin 0.26mg modified-release tabletsCST Pharma Ltd
- SpainMIRAPEXIN 0,26 mg COMPRIMIDOS DE LIBERACION PROLONGADABoehringer Ingelheim International Gmbh
- SwedenCalmolan 0,26 mg DepottablettG.L. Pharma GmbH
- ItalyMIRAPEXINBOEHRINGER INGELHEIM INTERNATIONAL GMBH
- FinlandMirapexinBoehringer Ingelheim International GmbH
- NetherlandsMirapexin 0,26 mg, tabletten met verlengde afgifteBoehringer Ingelheim International GmbH
- IcelandMirapexinBoehringer Ingelheim International GmbH*
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Calmolan, Calmolan Retard
- Bulgaria · Parson, Peximyr 0,18 Mg
- Cyprus · Medopexol, Rapexole
- Czechia · Calmolan, Glepark
- Germany · Glepark, Pexapral
- Denmark · Glepark, Mariprax
- Spain · Pramipexol Aurovitas, Pramipexol Aurovitas Spain
- Finland · Pramipexol, Pramipexol Stada
- France · Pramipexole Arrow Lab, Pramipexole Biogaran
- United Kingdom (Northern Ireland) · Pipexus, Pramipexole Glenmark Pharmaceuticals Europe
- Greece · Glepark, Mariprax
- Croatia · Pramipeksol Pliva
- Hungary · Calmolan, Erimexol
- Ireland · Miramel
- Iceland · Mirapexin, Oprymea
- Italy · Pramiperal, Pramipexolo Aurobindo
- Liechtenstein · Mirapexin, Pramipexole Teva
- Lithuania · Pramipexole Orion
- Luxembourg · Pramipexol Eg, Pramipexole Eg
- Latvia · Pramipexole Elvim, Pramipexole Orion
- Malta · Pramipexole Aurobindo
- Netherlands · Glepark, Pramipexol Aurobindo
- Norway · Mirapexin, Oprymea
- Portugal · Pramipexol Aurobindo, Pramipexol Azevedos
- Romania · Pramipexol Arena, Pramipexol Stada
- Sweden · Calmolan, Derinik
- Slovakia · Glepark, Pramipexol Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e592f086-39f5-4131-aacb-46493fa6ed7b GET /v1/drugs/e592f086-39f5-4131-aacb-46493fa6ed7b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Prolonged-release tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Pramipexol Teva 0.26 mg",
"name_fr": "Pramipexol Teva 0.26 mg",
"name_nl": "Pramipexol Teva 0.26 mg",
"amp_code": "SAM468764-00",
"strengths": [
"0.3750",
"0.3750",
"0.2600",
"0.2600"
],
"pack_count": 3,
"substances": [
"Pramipexole Dihydrochloride Monohydrate",
"Pramipexole"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Pramipexole",
"authorisation_numbers": [
"BE468764"
]
}See everything about pramipexole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.